Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MC4R | P32245 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | MC3R | P41968 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 3/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | F7 | P08709 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30373798 | 1.00 | ADORA3 (0.50) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL874457 | 0.81 | KDM4E (0.48) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL1838869 | 0.80 | ADORA3 (0.47) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL15572404 | 0.79 | IDO1 (0.48) | ADORA3TSHRMC4RADRA1AMC3R | |
| Hydrochloric Acid SCHEMBL1373071 | 0.79 | KDM4E (0.47) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL7299189 | 0.79 | IDO1 (0.44) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL4086758 | 0.79 | IDO1 (0.44) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL11642084 | 0.79 | BAZ2B (0.50) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL15571571 | 0.79 | KDM4E (0.47) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL15572500 | 0.79 | KDM4E (0.47) | ADORA3TSHRMC4RADRA1AMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630115-A1 | THERAPEUTIC COMPOUNDS | Sanofi (FR) | 2025-10-15 | — | — | EP | claimed |
| WO-2024121427-A1 | THERAPEUTIC COMPOUNDS | SANOFI (FR) | 2024-06-13 | — | — | WO | claimed |
| EP-2445889-A1 | NOVEL OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES | F. Hoffmann-La Roche AG (CH) | 2012-05-02 | — | — | EP | claimed |
| EP-2445868-A2 | NOVEL BIPHENYL AND PHENYL-PYRIDINE AMIDES | F. Hoffmann-La Roche AG (CH) | 2012-05-02 | — | — | EP | claimed |
| WO-2010149541-A1 | NOVEL OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-29 | — | — | WO | claimed |
| WO-2010149578-A2 | NOVEL BIPHENYL AND PHENYL-PYRIDINE AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-29 | — | — | WO | claimed |
| WO-2008099165-A1 | PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | WO | claimed |
| CN-115151252-B | Iron death inhibitor-diarylamine acetamides | 维泰瑞隆有限公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-115135648-B | Dihydronaphthyridones, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2024-02-09 | — | — | CN | disclosed |
| US-11737463-B2 | Pyridine and pyrazine compounds | BASF SE (DE) | 2023-08-29 | — | — | US | disclosed |
| CN-115135648-A | Dihydronaphthyridinone compounds, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2022-09-30 | — | — | CN | disclosed |
| US-20210145002-A1 | PYRIDINE AND PYRAZINE COMPOUNDS | BASF SE (DE) | 2021-05-20 | — | — | US | disclosed |
| CN-107001359-B | process for preparing praziquantel and precursors thereof | 默克专利股份有限公司 | 2019-12-17 | — | — | CN | disclosed |
| WO-2009077366-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND /OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| EP-1292579-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | Pharmacia Corporation (US) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001087854-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-11-22 | — | — | WO | disclosed |
| EP-0369743-B1 | Heterocyclic amides | ZENECA LTD (GB) | 1995-04-19 | — | — | EP | disclosed |
| CN-1072413-A | Amino acid derivative | HOFFMANN LA ROCHE (CH) | 1993-05-26 | — | — | CN | disclosed |
| EP-0369743-A2 | Heterocyclic amides | ZENECA LIMITED (GB) | 1990-05-23 | — | — | EP | disclosed |
| US-4046763-A | INTERMEDIATE FOR ULTRAVIOLET LIGHT ABSORBERS | MCNEIL LABORATORIES, INCORPORATED (US) | 1977-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11737463-B2 | Pyridine and pyrazine compounds | NDUFS5, IL5, NDUFS4 | ADORA3 1906/4885TSHR 3652/4885MC4R 360/4885 |
| US-20210145002-A1 | PYRIDINE AND PYRAZINE COMPOUNDS | NDUFS5, IL5, NDUFS4 | ADORA3 1906/4885TSHR 3652/4885MC4R 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.